Becton, Dickinson (BDX) Q2 FY2026 Earnings Call

Bottom line

The sleeper story is BD Excellence becoming a systematic competitive weapon, cutting R&D timelines by 10+ months while driving 8% productivity gains. The obvious headline is solid execution and raised guidance, but the underlying growth is decelerating despite easier comps and Q1 had artificial timing benefits. The binding constraint is quality control: the FDA warning letter and ChloraPrep ship hold show that post-remediation BD still has manufacturing issues that could derail the story. Most revealing quote: 'pending satisfactory results like we've seen for the product that we've been shipping to Europe' suggests they're not as confident as they sound. My view changes if the ChloraPrep testing extends beyond 3 weeks or fails, which would signal deeper quality problems and management credibility issues.

The 30-second version

BD Excellence is the sleeper story: 8% productivity gains are now systematically flowing into R&D and commercial
The $4B cash deployment math worked but the core business decelerated to 2.6%
ChloraPrep ship hold is a quality red flag they're downplaying as routine testing

What changed this quarter

Metric	Q1'26	Q2'26	Change
Revenue	$5.3B (+0.4% YoY in Q1)	$4.7B (+2.6% YoY)	+220 bps acceleration but lower absolute
Adjusted EPS	$2.91 (down 15.2% YoY)	$2.90 (+3.9% YoY)	Swing from -15% to +4% growth
Adjusted Operating Margin	21.2% (down 240 bps YoY)	24.2% (down 110 bps YoY)	+300 bps improvement, +130 bps less headwind
Connected Care Revenue	Mid-single digit growth	3.3% growth	Modest deceleration from prior trend
Advanced Patient Monitoring	High single digit growth	12% growth	Acceleration into double digits
Biologics Revenue Mix	50% of pharma systems revenue	55% of pharma systems revenue	+500 bps mix improvement
Alaris Market Share	100 bps gain in Q1	50 bps gain in Q2, 150 bps YTD	Share gain momentum maintained
Free Cash Flow YTD	$548M in Q1	$1.1B YTD	Strong cash conversion improvement
BD Excellence Productivity	8% in Q1	8% in Q2	Consistent world-class productivity
BioPharma Systems Revenue	Low single digit growth	-1.8% decline	Turned negative on vaccine headwinds

Accountability tracked

8 new promises made4 narrative shifts flagged6 prior promises scored

Inside the full report

The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.

Read the full BDX Q2'26 report Subscribe

Becton, Dickinson (BDX)

The 30-second version

What changed this quarter

Accountability tracked

Follow what management promises next